Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 25, 2012Quantitative Coronary Angiographic outcomes from PERSEUS and PLATINUM clinical trials presented at ACC 2012
Boston Scientific Corporation (NYSE: BSX) announces results from a quantitative coronary angiographic (QCA) analysis of the incidence of...
-
Mar 22, 2012Company's WallFlex Biliary Stents now available with a Transhepatic delivery system for use by interventional radiologists in treating obstructions within the biliary tract
Boston Scientific Corporation (NYSE: BSX) announces the U.S. and international launch of the WallFlex® Biliary Transhepatic Stent System. This...
-
Mar 20, 2012
Boston Scientific Corporation (NYSE: BSX) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the...
-
Mar 19, 2012Priority Health and HealthPartners issue new medical policies to cover catheter-based procedure shown to provide long-lasting control of severe asthma
Boston Scientific Corporation (NYSE: BSX) welcomes a milestone in private insurance reimbursement coverage for bronchial thermoplasty (BT) performed...
-
Mar 15, 2012Radiofrequency ablation catheter designed to treat a variety of arrhythmias
Natick, MA (March 15, 2012) -- Boston Scientific Corporation (NYSE: BSX) today announced Health Canada approval of the Blazer™ Open-Irrigated Catheter, the Company’s latest radiofrequency...
-
Mar 8, 2012Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San...
-
Mar 8, 2012
Boston Scientific Corporation (NYSE: BSX) and Lumenis, the market leader in holmium laser technology, announced the signing of a five-year contract...
-
Mar 1, 2012Next-generation coronary stent employs innovative alloy designed to improve acute performance
Boston Scientific Corporation (NYSE: BSX) announces the launch of the PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent System in...
-
Feb 23, 2012
Boston Scientific Corporation (NYSE: BSX) announces the first implants of a TELIGEN® implantable cardioverter defibrillator (ICD) in China. The...
-
Feb 22, 2012ION™ and TAXUS® Liberte® Paclitaxel-Eluting Stent Systems now approved for treating patients with acute myocardial infarction in the U.S.
Boston Scientific Corporation's (NYSE: BSX) ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting...